Drug that targets metabolic vulnerability and impairs cancer cell growth and survival ID'd

05:50 EDT 12 Jun 2018 | ecancermedicalscience

A drug discovered and advanced by The University of Texas MD Anderson Cancer Center's Institute for Applied Cancer Science (IACS) and the Center for Co-Clinical Trials (CCCT) inhibits a vital metabolic process required for cancer cells' growth and...

More From BioPortfolio on "Drug that targets metabolic vulnerability and impairs cancer cell growth and survival ID'd"